The company's lead asset, Mazindol ER, is in clinical development for narcolepsy and ADHD, targeting large patient populations. The merger combined NLS's small-molecule CNS focus with Kadimastem's cell therapies for neurodegenerative and metabolic diseases.
Cyborg Score Rationale
NLS faced repeated Nasdaq compliance challenges (2022-2024) related to minimum equity requirements before regaining compliance in October 2024. As a clinical-stage biotech with no approved products and limited financial resources, the company pursued merger strategy rather than standalone development.
Top Insights
(October 2025) Merger with Kadimastem completed; combined entity rebranded as NewCelX Ltd. and began trading under ticker NCEL
(October 2024) Regained full Nasdaq compliance with bid price and equity requirements after multiple delisting warnings
Lead candidate Mazindol ER (Quilience®) in clinical development for narcolepsy; prior Phase 2 completion in U.S.
Pipeline includes NLS-4 for sleep-related disorders and NLS-8 for neurodegenerative diseases
Named Competitors
Narcolepsy & ADHD therapeutics — Established narcolepsy treatment